Cyto-Histological Correlations in Pathology Diagnostics

A special issue of Reports (ISSN 2571-841X).

Deadline for manuscript submissions: 31 July 2024 | Viewed by 722

Special Issue Editor


E-Mail Website
Guest Editor
1. Head of Cytopathology, Fimlab Laboratories, 33100 Tampere, Finland
2. Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland
Interests: cytology; FNA; HPV primary screening; cardiovascular pathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

After a successful first edition of the Joint Special Issue “Cyto-Histological Correlations in Pathology Diagnostics” (https://www.mdpi.com/journal/diagnostics/special_issues/Cyto-Histopathogical; https://www.mdpi.com/journal/reports/special_issues/Cyto-Histo) with a total of 15 papers—including 10 original research papers and 2 case reports—dealing with various aspects of cyto-histological correlation and its role in cytological diagnosis, from gynecytology through effusions to fine-needle aspirations, we are pleased to announce a second edition.

Cyto-histological correlation is a comparison of cytological and histological diagnoses from the same lesion. It is a part of laboratory routine diagnostics at the case level and a quality assurance parameter if series-based. It mirrors our everyday routine diagnostics.

Series covering both gynecological and non-gynecological cytology, including fine needle aspirations, effusions, and brushing, are welcomed. Diagnostic issues and possible pitfalls should be discussed. Aspects of lesions imaging, sampling, processing, and staining can be highlighted in the cyto-histological correlation. Last but not least, as in the first edition, new and old cytology terminology series are encouraged as submissions.

You may choose our Joint Special Issue in Diagnostics.

Dr. Ivana Kholová
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cyto-histological correlation
  • pathology diagnostics
  • cytology terminology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 4668 KiB  
Article
Trophoblast Cell Surface Antigen 2 (Trop2) Is Expressed in Cases of EBV-Positive Diffuse Large B-Cell Lymphoma Emerging from Angioimmunoblastic T-Cell Lymphoma
by Susanne Ghandili, Judith Dierlamm, Carsten Bokemeyer, Clara Marie von Bargen, Anne Menz and Sören Alexander Weidemann
Reports 2024, 7(2), 37; https://doi.org/10.3390/reports7020037 - 14 May 2024
Viewed by 445
Abstract
Although trophoblast cell surface antigen 2 (Trop2)-targeting drugs are already approved or under investigation in various solid tumors, the significance of Trop2 in lymphoma is unknown. Thus, our objective was to investigate the expression of Trop2 in diffuse large B-cell lymphoma (DLBCL) through [...] Read more.
Although trophoblast cell surface antigen 2 (Trop2)-targeting drugs are already approved or under investigation in various solid tumors, the significance of Trop2 in lymphoma is unknown. Thus, our objective was to investigate the expression of Trop2 in diffuse large B-cell lymphoma (DLBCL) through a systemic immunohistochemistry screening. We constructed a tissue microarray comprising tissue from 92 DLBCL patients, each diagnosed at the University Medical Center Hamburg-Eppendorf (2020–2022). Trop2-immunohistochemistry was carried out, and positive staining was deemed a specific membranous positivity. Four samples were derived from Epstein-Barr virus (EBV)-positive DLBCL, with one case of EBV-positive DLBCL following angioimmunoblastic T-cell lymphoma (AITL). Strong Trop2 immunostaining was detectable in 1 of 91 analyzable samples, originating from a patient with a composite EBV-positive DLBCL emerging from AITL. Therefore, we performed an additional database search to identify all cases of composite EBV-positive DLBCL emerging from AITL since 2015. Five additional cases were identified and stained for Trop2, revealing two cases with strong B-blast positivity. Our preliminary data imply that Trop2 appears absent in de novo DLBCL, whereas Trop2 is strongly expressed in cases of a rare variant of EBV-positive DLBCL. Further investigations are needed to confirm our results, particularly on the subset of EBV-positive DLBCL emerging from AITL. Full article
(This article belongs to the Special Issue Cyto-Histological Correlations in Pathology Diagnostics)
Show Figures

Figure 1

Back to TopTop